Iliac Vein Stenting Shows Promise in Treating Post-Thrombotic Syndrome, With Cautious Risk-Benefit Profile

USA: In the phase III C-TRACT trial, endovascular therapy using iliac vein stenting combined with enhanced antithrombotic therapy in patients with moderate-to-severe post-thrombotic syndrome and iliac vein obstruction resulted in significant improvement in disease severity and health-related quality of life at 6 months compared to usual care. However, this benefit was accompanied by an increased overall risk of bleeding, although major bleeding events remained uncommon, indicating a favorable but cautious risk–benefit profile for clinical practice.